Novartis pays Abogen $575 million upfront for mRNA-encoded T-cell engager ABO2203

Novartis has agreed a licensing and option deal with China's Abogen Biosciences for ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, the companies announced on 2 October 2026 ¹. Abogen will receive an upfront payment of USD 575 million ¹.

The terms

Abogen is eligible for up to approximately USD 7.2 billion in potential milestone payments if all options on all programmes are exercised, subject to development, regulatory and commercial milestones, and may also receive royalties on future product sales ¹. BioPharma Dive put the total value at as much as $7.8 billion ². pharmaphorum described it as a deal that could be worth over $7.5 billion ³.

Abogen's announcement describes an exclusive worldwide licence to ABO2203, plus exclusive options for Novartis to license a number of next-generation assets developed on Abogen's RNA platform ¹. pharmaphorum also reports a worldwide licence ³. BioPharma Dive instead describes the upfront payment as buying an option to license ABO2203 ². The transaction is subject to customary closing conditions, including required regulatory clearances ¹.

ABO2203 is designed to use mRNA to direct the body's own production of T-cell engagers in vivo, rather than giving patients a recombinant engager made in the laboratory ¹². Abogen's chief executive, Bo Ying, said ABO2203 "is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases" ¹. Fiona Marshall, President of Biomedical Research at Novartis, said the approach "could complement existing therapeutic modalities by enabling in vivo production of these molecules" ¹.

Abogen describes its mRNA and LNP platform as AI- and automation-driven, covering mRNA design, formulation development and large-scale GMP manufacturing ¹. Its lead candidate, ABO1108, is a lyophilised mRNA shingles vaccine in Phase 3 trials in China ¹.

What it means for the market

The deal adds to a run of Western bets on Chinese multispecific biologics. BioPharma Dive data counts at least a dozen licensing deals for such drugs between US or European drugmakers and Chinese developers, and names Bristol Myers Squibb, Gilead Sciences and Vertex Pharmaceuticals among the large developers that bought into T-cell engager technologies this year ². pharmaphorum reports that Novartis is thought to be the first pharma multinational to partner with Abogen ³.

For Novartis the deal follows a difficult September. BioPharma Dive reports that Novartis paused a trial of its autoimmune CAR-T therapy after three patients died, that a genetic medicine developed with Ionis did not prove it could protect cardiovascular health, and that del-desiran, acquired with Avidity Biosciences, failed a key trial ². Jefferies analyst Michael Leuchten wrote on 8 September that those failures "will likely raise questions again about Novartis' due diligence and [business development] approach" ². pharmaphorum adds that Novartis faces the loss of market exclusivity for Entresto and other big-selling brands ³.

Makers of T-cell engagers have promoted them as a safer alternative to cell therapies, which are also costlier to manufacture ². pharmaphorum cites a Frost & Sullivan forecast that the T-cell engager category could be worth $121 billion by 2035 ³.

Caveats

The clinical evidence is early and comes from cancer, not autoimmune disease. Abogen presented early data in April from a study of ABO2203 in relapsed or refractory B-cell non-Hodgkin lymphoma, where it was well tolerated, though three patients had significant adverse events, including drops in white blood cell counts and in clotting proteins, which resolved over the course of the trial ². Most of the headline value depends on milestones and on Novartis exercising its options ¹. The deal still needs the required regulatory clearances before it closes ¹.